Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1992-07-13
1993-11-23
Friedman, S. J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
A61K 31135
Patent
active
052644596
ABSTRACT:
The present invention discloses improved methods for the treatment of autoimmune diseases using .beta.-adrenergic agonists, and particularly, .beta..sub.2 -adrenergic agonists. The treatment of animals with either EAE or EAN using the .beta..sub.2 -adrenergic agonist terbutaline significantly suppressed clinical disease. A Phase I safety treatment trial with terbutaline was conducted in MS patients. Twenty-four patients were treated for 4 weeks. No obvious side effects were observed. At 4 weeks, 15 of the 24 patients improved on neurologic rating scale and 17 patients reported subjective improvement. Treatment of rats with EAMG, an animal model of t
REFERENCES:
Beushausen, S., et al., "In Vivo and In Vitro Models of Demyelinating Disease: Activation of the Adenylate Cyclase System Influences JHM Virus Expression in Explanted Rat Oligodendrocytes," Journal of Virology, 61(12):3795-3803, 1987.
Chelmicka-Schorr, E., et al., "The .beta.-Adrenergic Agonist Isoproterenol Suppresses Experimental Allergic Encephalomyelitis in Lewis Rats," Journal of Neuroimmunology, 25:203-207, 1989.
Chelmika-Schorr, E., et al., "Treatment with .beta.-Adrenergic Agonist Isoproterenol Protects Against Development of Experimental Allergic Encephalomyelitis (EAE) in Rats," Neurology, 39(Suppl 1):330, 1989, Abstract p. 510.
Hoffman, Brian B., and Robert J. Lefkowitz, "Catecholamines and Sympathomimetic Drugs," In: Goodman and Gilman's the Pharmacological Basis of Therapeutics, Eighth Edition, pp. 187-220, 1990.
Karaszewski, Joseph W. et al., "Sympathetic Skin Responses Are Decreased and Lymphocyte Beta-Adrenergic Receptors Are Increased in Progressive Multiple Sclerosis," Annals of Neurology, 27(4):366-372, 1990.
Kirby, J. D. T. et al., "Prostacyclin Increases Cyclic-Nucleotide Responsiveness of Lymphocytes from Patients with Systemic Sclerosis," The Lancet, pp. 453-454, 1980.
Dialog Search Report.
Brosnan et al., "Prazosin, An .alpha..sub.1 -Adrenergic Receptor Antagonist, Suppresses Experimental Autoimmune Encephalomyelitis in the Lewis Rat," Proceedings of the National Academy of Science, USA, 82:5915-5919, 1985.
Chelmicka-Schorr and Arnason, "Nervous System-Immune System Interactions," In: Immunologic Mechanisms in Neurologic and Psychiatric Disease, B. H. Waksman, ed., Raven Press, New York, pp. 67-90, 1990.
Chelmicka-Schorr et al., "Sympathetic Nervous System (SNS) and Macrophage Function," Presented at 4th International Workshop on Neuroimmunomodulation, May, Florence, Italy, 1990.
Goldmuntz et al., "Prazosin Treatment Suppresses Increased Vascular Permeability in Both Acute and Passively Transferred Experimental Autoimmune Encephalomyelitis in the Lewis Rat," The Journal of Immunology, 137(11):3444-3450, 1986.
Karaszewski et al., "Increased Lymphocyte Beta-Adrenergic Receptor Density in Progressive Multiple Sclerosis is Specific for the CD8+, CD28-Suppressor Cell," Annals of Neurology, 30(1):42-47, 1991.
Levine et al., "Suppression of Experimental Allergic Encephalomyelitis by Stress," Proceedings of the Society of Experimental Biological Medicine, 109:294-298, 1962.
Reder et al., "Sympathetic Nervous System Involvement in Immune Responses of Mice and in Patients with Multiple Sclerosis," In: Neuroimmune Networks: Physiology and Diseases, E. J. Goetzl, Ed., Alan R. Liss, New York, pp. 137-147, 1989.
Arnason Barry G. W.
Chelmicka-Schorr Ewa E.
Cohen Louis
Reder Anthony T.
ARCH Development Corporation
Friedman S. J.
LandOfFree
Use of .beta.-adrenergic agonists to treat patients with demyeli does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of .beta.-adrenergic agonists to treat patients with demyeli, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of .beta.-adrenergic agonists to treat patients with demyeli will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1849212